InterventionsHuman trial

Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2

ADA Scientific Sessions 2026 Abstract

The paper

Andreea Ciudin, Beverly Tchang, Amelia J. Balmain,

Suzanne R. Klise, Donna Mojdami, Wenyu Ye, Xiaojuan Mi,

Hunter T. Hoffmann

Barcelona

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 1716-P

doi.org/10.2337/db26-1716-p

Orforglipron matches insulin glargine on cardiovascular safety
Lancet · 4 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Cell Metabolism · 8 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Lancet · 4 Oct 2026